pamidronate has been researched along with CKD-MBD in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 7.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 3.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "In the distal femur, a high-turnover renal osteodystrophy was found but pamidronate suppressed this bone turnover and increased bone mineral content." | 1.35 | Treatment of experimental renal osteodystrophy with pamidronate. ( Iwaniec, UT; Järvinen, TL; Jokihaara, J; Jolma, PM; Kannus, P; Kööbi, P; Mustonen, JT; Pörsti, IH; Saha, HH; Sievänen, H; Turner, RT, 2008) |
| "While patients with renal osteodystrophy react favorably to supplementation of active vitamin D metabolites to prevent or reverse renal osteodystrophy, the use of these drugs is bound to result in greater hypercalcemia in those patients who are already hypercalcemic." | 1.28 | No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. ( de bos Kuil, RJ; Dorhout Mees, EJ; Duursma, SA; Hené, RJ; Raymakers, JA; Visser, WJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saghafi, D | 1 |
| Lu, KC | 1 |
| Yeung, LK | 1 |
| Lin, SH | 1 |
| Lin, YF | 1 |
| Chu, P | 1 |
| Jokihaara, J | 1 |
| Pörsti, IH | 1 |
| Kööbi, P | 1 |
| Jolma, PM | 1 |
| Mustonen, JT | 1 |
| Saha, HH | 1 |
| Sievänen, H | 1 |
| Kannus, P | 1 |
| Iwaniec, UT | 1 |
| Turner, RT | 1 |
| Järvinen, TL | 1 |
| Hené, RJ | 1 |
| Visser, WJ | 1 |
| Duursma, SA | 1 |
| Raymakers, JA | 1 |
| de bos Kuil, RJ | 1 |
| Dorhout Mees, EJ | 1 |
4 other studies available for pamidronate and CKD-MBD
| Article | Year |
|---|---|
Use of bisphosphonates in patients with myeloma and renal failure.
Topics: Antineoplastic Agents; Bone Remodeling; Chronic Kidney Disease-Mineral and Bone Disorder; Contraindi | 2003 |
Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcemi | 2003 |
Treatment of experimental renal osteodystrophy with pamidronate.
Topics: Animals; Bone Demineralization, Pathologic; Bone Density; Bone Remodeling; Chronic Kidney Disease-Mi | 2008 |
No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
Topics: Adult; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcem | 1990 |